Steve Bryson, PhD, science writer —

Itaconate, a metabolite produced during cellular energy production activities, was found to restore the balance of immune T cells and reduce multiple sclerosis (MS) symptoms in a mouse model of the disease, a study reported. The common metabolite specifically suppressed the production of pro-inflammatory T cells while promoting the…

The body has two distinct lineages of immune cells that can be distinguished by the presence or absence of the vitamin D receptor, a preclinical study reports. The findings shed more light on how vitamin D fine-tunes immune responses and may help researchers better understand the link between vitamin…

Supplementation with phosphoenolpyruvate (PEP), a molecule produced during cellular energy generation, eased the signs and symptoms of multiple sclerosis (MS) in a mouse model of the disease, a study revealed. The metabolite inhibited a protein called JunB, which blocked the production of the pro-inflammatory molecule interleukin-17 (IL-17) and suppressed…

Using Mayzent (siponimod) and vitamin D3 as a combination therapy was found to improve motor function and promote remyelination — restoring the damaged myelin sheath around nerve fibers —  in a mouse model of multiple sclerosis (MS). “Our results demonstrate for the first time the potential synergistic effects…

Two alternative treatments for the cognitive challenges people with multiple sclerosis (MS) can face in daily life — cognitive rehabilitation therapy (CRT) and mindfulness-based cognitive therapy (MBCT) — were found to helpful in a clinical trial. Patients randomized to either treatment approach in the REMIND-MS study had fewer…

The signaling protein fractalkine was found to promote the repair of myelin — the protecting coating around nerve fibers — that is damaged by the mistaken immune attack that leads to multiple sclerosis (MS), a mouse study demonstrated. In an animal model of the disease, the molecule…

Teenagers with poor sleep quality or insufficient sleep — those who sleep less than seven hours a night — are 40% to 50% more likely to develop multiple sclerosis (MS) later in life than those who get adequate rest, according to a Swedish population-based study. Differences in sleep timing…

Within the first 12 years after the onset of symptoms, about one-fourth of people with clinically isolated syndrome — or a first episode of multiple sclerosis (MS) symptoms — showed a worsening of disability independent of relapses, a study reports. This type of disease progression, called progression independent…

Uses of virtual reality-based physiotherapy to improve balance and gait in people with multiple sclerosis (MS) are linked to lower dropout rates than those found with conventional rehabilitation methods, a review of clinical trials suggested. Although the difference between the two physiotherapy approaches was not statistically significant, adherence to…

The risk of developing multiple sclerosis (MS) doesn’t seem to be influenced by consuming alcohol, according to a large-scale analysis in the U.K. After adjusting for known MS risk factors, including smoking, childhood obesity, socioeconomic status, or genetics, the findings remained the same. The analysis was published in Nature…

A stem cell transplant more effectively slowed disability worsening in people with active secondary progressive multiple sclerosis (SPMS) than anti-inflammatory treatments and disease-modifying therapies (DMTs), a study has found. More transplant recipients also experienced clinical improvements that were sustained after three and five years. After 10 years,…

Myelin, the fatty-rich material surrounding nerve fibers that’s progressively damaged in multiple sclerosis (MS), provides metabolic support to a type of nerve cell in the brain that controls the activity of other nerve cells, a study discovered. Researchers showed mitochondria, the cell’s energy producers, are specifically clustered in…

People with relapsing-remitting multiple sclerosis (RRMS) have elevated levels of the lipocalin 2 (Lcn-2) protein in their stool samples, a marker for intestinal inflammation, compared with healthy controls, a study demonstrated. Among patients, findings also demonstrated those with high fecal Lcn-2 had changes in their gut microbiome, the collection…

The risk of transitioning from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) declined significantly after the introduction of disease-modifying therapies (DMT), according to a large nationwide Swedish study. Data showed that SPMS conversion risk rose by 3% each year before the first generation of…

Kesimpta (ofatumumab) may be more effective at reducing relapse rates than other disease-modifying therapies (DMTs) in Japanese adults with relapsing forms of multiple sclerosis (MS), according to a review of clinical trial data. Although the differences were not statistically significant, the study provided comparative evidence that may help…

Taking the pregnancy hormone estriol in combination with Copaxone (glatiramer acetate) significantly reduced the blood levels of neurofilament light chain (NfL) — a marker of nerve damage — in women with relapsing-remitting multiple sclerosis (RRMS), clinical trial data show. These lower NfL levels were significantly associated with a…

A new tool called signal detection theory (SDT) found a relationship between subjective cognitive fatigue, often experienced by people with multiple sclerosis (MS), and the activation of certain brain regions, a study reported. Although the relationship was found in both patients and healthy controls after cognitive fatigue was…

Treatment with the approved multiple sclerosis (MS) therapy dimethyl fumarate (DMF) did not affect the function of the thyroid gland, an organ that secretes hormones to regulate metabolism, a medical records study concluded. Screening for thyroid problems is not needed for people with MS considered for DMF therapy, the…

Multiple sclerosis (MS) patients treated with Betaseron (interferon beta-1b) had over 90% treatment compliance — the percentage of doses administered — over one year, according to a study of data collected by the BETACONNECT autoinjector and the myBETAapp. After one year, the number of patients still using Betaseron…

A team of researchers has discovered that the key to bypassing the blood-brain barrier — a semipermeable border that protects the brain against toxins in the blood but also blocks potential treatments — is the Unc5B receptor in the endothelial cells that line the tiny blood vessels in the brain.

For the first time, researchers have brought to light the precise three-dimensional structure of Mayzent (siponimod) as it binds to its molecular target, the sphingosine 1-phosphate receptor 1 (S1P1). These findings are expected to aid in developing next-generation MS therapeutics with better selectivity for S1P1, enhancing their potency while reducing…

Paralyzed Veterans of America (PVA) has formed a committee to better address the needs and interests of veterans with multiple sclerosis (MS), including help with obtaining care and disability benefits. The nonprofit PVA is the only congressionally chartered veterans organization working to assist and represent veterans with spinal…

Multiple sclerosis (MS) patients reported fewer difficulties regulating their emotions, and reduced depressive symptoms when they applied trait mindfulness techniques, a study showed. Trait mindfulness refers to an innate ability to pay and maintain attention to moments in the present with an open, non-judgmental attitude. Notably, the use of…

The psychological distress of a parent whose child is found to have multiple sclerosis (MS) may directly impact the quality of life of the child. That’s according to a new study that revealed a worse health-related quality of life (HRQoL) in MS children after their diagnosis. These findings support…

An increased production of CD25 – an immune receptor that regulates T-cell proliferation and activation – is the most noticeable blood cell immune alteration in people with multiple sclerosis (MS) compared with their unaffected identical twins, a study discovered. The increased CD25 levels, which correlated with disease severity, were…

Therapeutics designed to produce new oligodendrocytes — the cells responsible for the protective myelin sheath that is damaged in multiple sclerosis (MS) — might be the most effective approach for disorders such as MS, according to a study conducted in a fish model. That’s because oligodendrocytes that survive being…

VISIONARY-MS, a Phase 2 clinical trial evaluating the safety and effectiveness of CNM-Au8 in people with relapsing multiple sclerosis (MS) with disease-related visual impairment, will conclude early due to COVID-19 pandemic-related challenges. The release of trial data is expected in the second half of this year, according to…

Exergames — playing video games that involve physical exercise — may be more effective at improving balance in people with multiple sclerosis (MS) than conventional rehabilitation, a review of current studies suggested. The study, “Efficacy of Virtual Reality and Exergaming in Improving Balance in Patients With…

Vitamin D supplementation may improve quality of life in people with multiple sclerosis (MS), according to a literature review study. Because vitamin D deficiency is common in MS patients, these findings suggest that “supplementation should be applied at least in a dose that covers the recommended intake,” the researchers…

A higher dose of Copaxone (glatiramer acetate) given three times weekly over seven years led to sustainably lower relapse rates and slowed disability progression in multiple sclerosis (MS) patients, according to a long-term analysis of the GALA study. The higher dose — 40 mg/mL — was generally well-tolerated with no…